Embecta(EMBC)
PARSIPPANY, NJBiotechnology
Focus: Embecta is a publicly traded diabetes care company focused on insulin delivery devices and automated insulin delivery systems for metabolic diseases. With $1.1B in annual revenue and a profitable operating model, it operates as a specialized player in the diabetes technology segment.
Profile data last refreshed 5h ago · AI intelligence enriched 1mo ago
Funding Stage
PUBLIC
Open Jobs
31+127 this month
Hot — 151 jobs added in 30d
Net +127 (151 new, 24 removed). Aggressive expansion phase.
Should You Work at Embecta?
AI assessmentBest suited for commercial or device-focused professionals in diabetes care; limited appeal for pipeline-driven researchers or those seeking rapid organizational growth.
Why Work Here
- Profitable, publicly traded company with $268M cash position and $70M net income in FY2025, providing financial stability for career development
- Leadership actively expanding with recent appointment of North America President (June 2026), signaling organizational growth and advancement opportunities
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Early-stage
2 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$1.1B
Pipeline & Clinical Trials
An AID System.
Type 2 DiabetesClinical Trials (1)
NCT06692153Embecta AID System in Adults With Type 2 Diabetes
N/AHelp build intelligence for Embecta
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.